18:34 , Mar 8, 2017 |  BC Innovations  |  Translation in Brief

Up to eleven

Factor XI inhibitors may not only have safety advantages over more established anticoagulants, but could come with blood pressure-lowering benefits as well. A Science Translational Medicine study from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Johannes Gutenberg...
19:07 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Mouse and rat studies suggest inhibiting Factor XI could help treat arterial hypertension and consequent tissue damage. In a mouse model of arterial hypertension, an antisense oligonucleotide targeting Factor XI decreased blood pressure and...
20:40 , Feb 17, 2017 |  BC Week In Review  |  Company News

Ionis, Bayer deal

Ionis will receive a $75 million milestone payment from Bayer tied the development of anticoagulants IONIS-FXIRx (BAY 2306001) and IONIS-FXI-LRx, both Factor XI antisense inhibitor. The partners share rights to IONIS-FXIRx under a 2015 deal...
22:50 , Feb 14, 2017 |  BC Extra  |  Company News

Ionis gets $75M milestone in Bayer anticoagulant deal

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) is to receive a $75 million milestone payment from Bayer AG (Xetra:BAYN) tied to milestones in the development of Factor XI antisense inhibitors IONIS-FXIRx (BAY 2306001) and IONIS-FXI-LRx. The partners share...
11:41 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

IONIS-FXIRx: Ph II data

A double-blind, Canadian Phase II trial in 43 patients with ESRD receiving hemodialysis showed that 200 and 300 mg doses of subcutaneous IONIS-FXIRx dosed twice weekly for 2 weeks and then once weekly for 10...
07:00 , Sep 29, 2016 |  BC Innovations  |  Product R&D

Safety Factor

Although the advent of Factor Xa inhibitors improved quality of life for many thrombosis patients, the compounds' bleeding risk prevents use in patient populations with certain co-morbidities, and has prompted a handful of companies to...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ISIS 416858: Phase II started

Isis began a double-blind, placebo-controlled, Canadian Phase II trial to evaluate 200 and 300 mg subcutaneous ISIS 416858 twice weekly for 2 weeks and then once weekly for 10 weeks in about 53 patients. Isis...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Isis Pharmaceuticals, Bayer deal

Isis granted Bayer exclusive, worldwide rights to develop and commercialize ISIS-FXIRx to prevent thrombosis. Bayer plans to evaluate the Factor XI antisense inhibitor in patients who are unable to use available anticoagulants, including...
01:09 , May 5, 2015 |  BC Extra  |  Company News

Bayer licenses anticoagulant from Isis

Bayer AG (Xetra:BAYN) gained exclusive, worldwide development and commercialization rights to anticoagulant candidate ISIS-FXIRx from Isis Pharmaceuticals Inc. (NASDAQ:ISIS) for $100 million up front. Isis is eligible for a $55 million milestone after completing a...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

ISIS-FXIRx: Phase II final data

Final data from an open-label, international Phase II trial in 293 patients undergoing total knee replacement surgery showed 26.9% of patients receiving 200 mg subcutaneous ISIS-FXIRx and 4.2% of patients receiving 300 mg subcutaneous ISIS-FXIRx...